僵直性脊椎炎治疗市场规模、份额、成长分析（按治疗类型、按药物类型、按最终用户、按地区）- 产业预测，2025 年至 2032 年

Ankylosing Spondylitis Treatment Market Size, Share, and Growth Analysis, By Treatment Type (NSAIDs, Biologics ), By Drug Type, By End-User, By Region - Industry Forecast 2025-2032

出版日期: 2025年06月11日 | 出版商:

SkyQuest | 英文 198 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球僵直性脊椎炎治疗市场规模预计在 2023 年达到 31 亿美元，到 2032 年将达到 60.9 亿美元，预计在预测期内（2025-2032 年）的复合年增长率为 7.8%。

僵直性脊椎炎（AS）的发生率不断上升，尤其是在年轻人和中年人中，这推动了市场扩张。 AS 是一种严重影响脊椎和荐髂关节的自体免疫慢性疾病，主要由 HLA-B27 基因等遗传因素引起，在欧洲、北美和亚洲部分地区等地区很常见。随着认识和诊断能力的提高，对透过早期诊断进行长期管理和创新治疗的需求日益增长。生物疗法，尤其是肿瘤坏死因子（TNF）抑制剂和白细胞介素-17（IL-17）阻断剂，由于其能够特异性针对发炎途径而成为首选。正在进行的研究和开发旨在开发下一代生技药品，加强生技药品在治疗方案中的关键作用并推动市场成长。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业市场定位（2024年）
主要市场参与者所采取的策略
近期市场趋势
公司市场占有率分析（2024年）
主要企业简介
- 公司详情
- 产品系列分析
- 公司分部份额分析
- 收益与前一年同期比较对比（2022-2024 年）
  主要企业简介
  - 艾伯维公司（美国）
  - 诺华公司（瑞士）
  - 强生公司（美国）
  - 辉瑞公司（美国）
  - 安进公司（美国）
  - UCB SA（比利时）
  - 百时美施贵宝（美国）
  - 礼来公司（美国）
  - 罗氏控股公司（瑞士）
  - 默克公司（美国）
  - Biogen公司（美国）
  - Celgene公司（美国）
  - 武田药品工业株式会社（日本）
  - 拜耳公司（德国）
  - 再生元製药（美国）
  - 梯瓦製药工业股份有限公司（以色列）
  - Sandoz International GmbH（瑞士）
  - 鲁宾有限公司（印度）
  - 迈兰公司（美国）

结论和建议

简介目录

Product Code: SQMIG35D2295

Global Ankylosing Spondylitis Treatment Market size was valued at USD 3.1 billion in 2023 and is poised to grow from USD 3.34 billion in 2024 to USD 6.09 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

The rising prevalence of ankylosing spondylitis (AS), particularly among young and middle-aged adults, is significantly influencing market expansion. AS, an autoimmune chronic disorder that severely impacts the spine and sacroiliac joints, is predominantly driven by genetic factors such as the HLA-B27 gene, especially prevalent in regions like Europe, North America, and parts of Asia. As awareness and diagnostic capabilities improve, earlier diagnoses lead to an increased demand for long-term management and innovative treatments. Biologic therapies, notably tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) blockers, are becoming the preferred choice due to their ability to specifically target inflammation pathways. Ongoing research aims to develop next-generation biologics, reinforcing their critical role in therapeutic options and catalyzing market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Treatment Market Segments Analysis

Global Ankylosing Spondylitis Treatment Market is segmented by Treatment Type, Drug Type, End-User and region. Based on Treatment Type, the market is segmented into NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Biologics (TNF Inhibitors, IL-17 Inhibitors), DMARDs (Disease-Modifying Anti-Rheumatic Drugs), Physical Therapy & Exercise and Others. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on End-User, the market is segmented into Hospitals & Clinics, Specialty Clinics and Home Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Treatment Market

The rising global incidence of ankylosing spondylitis, especially in younger demographics, serves as a significant catalyst for the market. As more individuals receive a diagnosis, there is a growing need for effective treatment options. In response to this surge in therapeutic requirements, healthcare systems and pharmaceutical companies are dedicating increased resources to the development of innovative drugs, advanced diagnostic tools, and patient-centered care approaches. This trend highlights the urgency to meet the evolving needs of patients suffering from ankylosing spondylitis, further stimulating market growth and fostering advancements in treatment solutions.

Restraints in the Global Ankylosing Spondylitis Treatment Market

The Global Ankylosing Spondylitis Treatment market faces significant restraints, particularly in emerging markets where a lack of general practitioner awareness and low patient knowledge lead to delayed diagnoses of this condition. Such delays can result in advanced disease progression and reduced effectiveness of treatment options. Furthermore, the shortage of skilled rheumatologists and the absence of comprehensive initial screening programs exacerbate these challenges, ultimately hindering overall market growth. Addressing these barriers is essential to enhance early detection and ensure optimal management of ankylosing spondylitis, thereby improving patient outcomes and stimulating market development.

Market Trends of the Global Ankylosing Spondylitis Treatment Market

The Global Ankylosing Spondylitis Treatment market is witnessing a significant trend towards biologics, particularly TNF and IL-17 inhibitors, which are redefining therapeutic approaches due to their targeted mechanisms and improved efficacy. This shift is propelled by robust ongoing research and development, coupled with the expansion of biosimilar options, making these advanced therapies more accessible and cost-effective. As healthcare providers and patients seek long-term disease control and enhanced quality of life, the preference for biologic treatments continues to solidify, stimulating market growth. This transition underscores the evolving landscape of ankylosing spondylitis management and underscores the importance of innovation in therapeutic regimens.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Analysis

Global Ankylosing Spondylitis Treatment Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
Biologics (TNF Inhibitors, IL-17 Inhibitors)
DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
Physical Therapy & Exercise
Others

Global Ankylosing Spondylitis Treatment Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Branded Drugs
Generic Drugs

Global Ankylosing Spondylitis Treatment Market Size by End-User & CAGR (2025-2032)

Market Overview
Hospitals & Clinics
Specialty Clinics
Home Care

Global Ankylosing Spondylitis Treatment Market Size & CAGR (2025-2032)

North America (Treatment Type, Drug Type, End-User)
- US
- Canada
Europe (Treatment Type, Drug Type, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Drug Type, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Drug Type, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Drug Type, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AbbVie Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments